ConductScience.org, home

Paper41397686

Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs.

Hong JH and 14 others. Diabetes Metab J, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs. Papers, record 41397686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41397686

Download JSON
Disease
type 2 diabetes mellitus613 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs.
PubMed
Journal
Diabetes Metab J
PubMed
Year
2026
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Multicenter Study
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-16
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hong JHJun Hwa
2Min KWKyung Wan
3Lee CBChang Beom
4Chamnan PParinya
5Sirirak TThanitha
6Sony KKiran
7Sattanon SSarinya
8Kim HJHae Jin
9Kim SYSang-Yong
10Kim YYounghee
11Heo JAJung A
12Cho JMJae Min
13Nah JJJae Jin
14Park MHMi Hee
15Kim JHJae Hyeon

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Diabetes Mellitus, Type 2Major topic
Hypoglycemic AgentsMajor topic
InsulinMajor topic
Benzhydryl CompoundsMajor topic
Sodium-Glucose Transporter 2 InhibitorsMajor topic
Humans
Female
Male
Middle Aged
Double-Blind Method
Glycated Hemoglobin
Drug Therapy, Combination
Blood Glucose
Adult
Treatment Outcome
Republic of Korea
Aged
Thailand
Benzofurans
Glucosides

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Daewoong Pharmaceutical Co., LtdPubMed

Source PubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT05466643A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes MellitusDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125468945Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.Diabetes Care2015https://conductscience.org/library/papers/25468945PubMed
228371205
Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
Diabetes Obes Metab2017https://conductscience.org/library/papers/28371205PubMed
326040302Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.Diabetes Obes Metab2015https://conductscience.org/library/papers/26040302PubMed
425003073Current status of glycemic control of patients with diabetes in Korea: the fifth Korea national health and nutrition examination survey.Diabetes Metab J2014https://conductscience.org/library/papers/25003073PubMed
531692244Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.Diabetes Obes Metab2020https://conductscience.org/library/papers/31692244PubMed
640367988SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application.Diabetes Metab J2025https://conductscience.org/library/papers/40367988PubMed
7396519816. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025.Diabetes Care2025https://conductscience.org/library/papers/39651981PubMed
822517736
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Diabetes Care2012https://conductscience.org/library/papers/22517736PubMed
936906135
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study.
Diabetes Metab2023https://conductscience.org/library/papers/36906135PubMed
1031478335Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).Diabetes Obes Metab2020https://conductscience.org/library/papers/31478335PubMed
1124529566Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.Diabetes Res Clin Pract2014https://conductscience.org/library/papers/24529566PubMed
1227181422Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.J Diabetes Investig2016https://conductscience.org/library/papers/27181422PubMed
1335395697Dose-dependent glucosuria of DWP16001, a novel selective sodium-glucose cotransporter-2 inhibitor, in healthy subjects.Br J Clin Pharmacol2022https://conductscience.org/library/papers/35395697PubMed
1437421885Role of novel sodium glucose co-transporter-2 inhibitor enavogliflozin in type-2 diabetes: A systematic review and meta-analysis.Diabetes Metab Syndr2023https://conductscience.org/library/papers/37421885PubMed
1522431673Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.Ann Intern Med2012https://conductscience.org/library/papers/22431673PubMed
1627316668Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.Cardiovasc Diabetol2016https://conductscience.org/library/papers/27316668PubMed
1725852208
Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
Diabetes Care2015https://conductscience.org/library/papers/25852208PubMed
1829165885The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis.Obesity (Silver Spring)2018https://conductscience.org/library/papers/29165885PubMed
1927987240Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial.Diabetes Obes Metab2017https://conductscience.org/library/papers/27987240PubMed
2036756676Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial.Diabetes Metab J2023https://conductscience.org/library/papers/36756676PubMed

See all 49 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42941823Insulin Intensification and Simplification Strategies in Patients with Type 2 Diabetes and Overweight or Obesity: A Scoping Review.Int J Mol Sci2026https://conductscience.org/library/papers/42941823

Source PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene
SLC5A26524PubTator's text mininghttps://conductscience.org/library/genes/6524NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
ENAVOGLIFLOZINCHEMBL3703921Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3703921

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41397686

GET https://conductscience.org/api/papers/v1/41397686/references?page=2